Q-omics provides the consensus-scored TRAJ12 profile across patient tissues and cancer cell-line models. TRAJ12 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TRAJ12 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TRAJ12 RNA expression shows 12,425 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, KIRC, and LSCC as cancer lineages where TRAJ12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ12 survival associations across molecular data types. TRAJ12 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ12 RNA expression–survival associations across cancer types. High TRAJ12 expression shows unfavorable associations in LUSC and LGG, but favorable associations in SKCM, UCEC, LUAD and ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify LUSC as the clearest survival context for TRAJ12 RNA expression.
This table summarizes TRAJ12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ12 shows lower tumor expression in THCA and higher tumor expression in KIRC, STAD and LIHC. The KIRC box plot shows higher TRAJ12 RNA expression in tumor versus normal tissue (log2 FC = +0.409, t-test p < 0.001).
This table shows molecular features associated with TRAJ12 in patient tissues and cancer cell lines. In patient samples, TRAJ12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
